抗心律失常治疗心力衰竭的治疗方法
Hilke Könemann1, Sati Güler-Eren2, Christian Ellermann2
1Department of Cardiology II: Electrophysiology, University Hospital Münster, Münster, Germany. hilke.koenemann@ukmuenster.de.
Current heart failure reports
|January 15, 2024
概括
心力衰竭中的心律失常会增加死亡风险. 早期节律控制,导管切除和ICD治疗是关键的,而药物治疗是辅助的,需要多模式的方法以获得最佳的患者结果.
科学领域:
- 心脏病学 心脏病学
- 电力生理学 电力生理学
- 心脏衰竭管理的管理
背景情况:
- 心律失常在心力衰竭 (HF) 患者中很普遍,显著增加死亡率和发病率风险.
- 有效的抗心律失常策略对于治疗心力衰竭患者至关重要.
研究的目的:
- 审查目前治疗心力衰竭患者心律失常的治疗方法.
- 突出最近的进展和基于证据的策略,在抗心律失常治疗HF.
主要方法:
- 审查当前的临床指南和最近的临床试验数据.
- 对药物学,基于器械 (ICD) 和干预 (导管切除) 疗法的分析.
- 整合指导方针导向的医疗治疗HF与抗心律失常干预.
主要成果:
- 早期节律控制和导管切除显示出预后益处,特别是在减少射出分数的高频率中.
- 植入式心脏转换器-除器 (ICD) 治疗对于预防心脏突然死亡至关重要,尽管风险分层仍然具有挑战性.
- 抗心律失常药物治疗在症状缓解方面起到辅助作用,没有预后益处,并带有预心律失常风险.
结论:
- 在HF中,抗失常疗法需要一个系统的,多式模式的策略.
- 整合药物,器械和干预治疗与HF指导方针导向的医疗治疗是必不可少的.
- 优化抗心律失常管理可以改善心力衰竭和心律失常患者的治疗结果.
相关概念视频
Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K
Disturbances in Heart Rhythm
961
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
961
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
746
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
746
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432


